FIGURE 1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
Year: 2024
Type: other
Abstract: Clinical efficacy of TPST-1120 monotherapy (A, B) and in combination with nivolumab (C, D). In swimmer plots shown in A and C, study treatment discontinuations for other than disease progression are shown as *Adverse event, ^Symptomatic deterioration, #Investigator decision, or §Consent withdrawn. For monotherapy, scans were every 6 weeks until week 12, followed by an increase to 9-week intervals between scans. For combination therapy, scans occurred every 8 weeks. The RCC responder in the 600 mg BID + nivolumab dose group had an unscheduled scan at day 24 during hospitalization for treatment-unrelated AEs. This patient discontinued treatment one day prior to the scan but was unable to restart and had disease progression during the posttreatment follow-up period. BID, twice daily; CCA, cholangiocarcinoma; CRC, colorectal carcinoma; HCC, hepatocellular carcinoma; mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non–small cell lung cancer; Panc, pancreatic cancer; PD, progressive disease; PR, partial response; RCC, renal cell carcinoma; SD, stable disease.
Authors: Mark Yarchoan, John D. Powderly, Bruno R. Bastos, Thomas B. Karasic, Oxana V. Crysler, Pamela N. Munster, Meredith A. McKean, Leisha A. Emens, Yvonne M. Saenger, Yasser Ged, Robert Stagg, Steven Smith, Chan C. Whiting, Anne Moon, Peppi Prasit, Yonchu Jenkins, Nathan Standifer, Thomas W. Dubensky, Sam H. Whiting, Susanna V. Ulahannan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4394915006